Low-dose decitabine and high-risk MDS.
Raza
Azra
A
Raza
Fatima Zehra
FZ
Galili
Naomi
N
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077209:Decitabine; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008745:Methylation / Q000187:drug effects; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000096:biosynthesis; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012307:Risk Factors
D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; D000077209:Decitabine; D001374:Azacitidine